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nKg2h-expressing T cells 
negatively regulate immune 
responses
Daniela Dukovska, Daniel Fernández-Soto, Mar Valés-Gómez and Hugh T. Reyburn*
Department of Immunology and Oncology, National Centre for Biotechnology, CSIC, Madrid, Spain
The biology and function of NKG2H receptor, unlike the better characterized members of 
the NKG2 family NKG2A, NKG2C, and NKG2D, remains largely unclear. Here, we show 
that NKG2H is able to associate with the signaling adapter molecules DAP12 and DAP10 
suggesting that this receptor can signal for cell activation. Using a recently described 
NKG2H-specific monoclonal antibody (mAb), we have characterized the expression 
and function of lymphocytes that express this receptor. NKG2H is expressed at the cell 
surface of a small percentage of peripheral blood mononuclear cell (PBMC) and is found 
more frequently on T cells, rather than NK cells. Moreover, although NKG2H is likely to 
trigger activation, co-cross-linking of this receptor with an NKG2H-specific mAb led to 
decreased T cell activation and proliferation in polyclonal PBMC cultures stimulated by 
anti-CD3 mAbs. This negative regulatory activity was seen only after cross-linking with 
NKG2H, but not NKG2A- or NKG2C-specific monoclonal antibodies. The mechanism 
underlying this negative effect is as yet unclear, but did not depend on the release of 
soluble factors or recognition of MHC class I molecules. These observations raise the 
intriguing possibility that NKG2H may be a novel marker for T cells able to negatively 
regulate T cell responses.
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inTrODUcTiOn
The NKG2 family of receptors are type II transmembrane glycoproteins containing an extracellular 
C-type lectin-like domain, encoded in a gene cluster on human chromosome 12p12-p13 and mainly 
expressed by NK cells and subsets of T cells (1). NKG2 family receptors are divided into inhibitory 
and activating forms (2, 3). NKG2A/2B receptors contain cytoplasmic immunoreceptor tyrosine-
based inhibitory motifs (ITIM) and function as inhibitory receptors (4). By contrast, NKG2C, 
NKG2F, and NKG2E/2H receptors are generally classed as activating receptors, since they contain a 
lysine residue in the transmembrane region allowing association with the ITAM-containing adapter 
protein DAP12 (5). NKG2D protein also has a charged amino acid in the transmembrane domain, 
but in humans only associates with the signaling adapter molecule DAP10 and not DAP12 (6, 7). 
The biology and functions of the NKG2A, NKG2C, and NKG2D receptors in immune responses to 
infections and in cancer have been studied extensively (8, 9); however, only very little is known about 
the biology of the other members of this family: NKG2F, NKG2E, and NKG2H.
The NKG2F gene encodes a receptor with a truncated extracellular domain without a lectin-like 
domain (10) and, although NKG2F protein is expressed in NK cells and can associate with DAP12, 
this receptor is only found intracellularly (11). It is not clear if this receptor has any function in 
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NK  cell activation or whether it is simply a “fossil” within the 
NKG2 gene family.
NKG2E mRNA has been detected in NK cells and CTL (12–15), 
but, due to the lack of a specific antibody, expression of NKG2E 
protein has not been demonstrated. Soluble recombinant NKG2E 
protein, in complex with CD94, has been reported to bind HLA-E 
(16); however in transfected cells, NKG2E did not reach the cell 
surface, despite associating with CD94 and DAP12 (17).
NKG2H is an alternative splice form of NKG2E in which intron 
VI is not removed and exon VII is not present. This alteration 
deletes the sequence responsible for the intracellular retention of 
NKG2E and gives rise to a specific 33 amino acid sequence located 
at the membrane distal portion of the extracellular domain of 
the NKG2H protein. Previous studies have demonstrated that 
generation of the splice variants NKG2E and -H seems to occur 
at a constant ratio (12) and that mRNA for NKG2H can be found 
in both NK cells and CTL (12, 18). Like NKG2C and NKG2E, 
NKG2H has a short cytoplasmic tail and lacks ITIMs, but does 
possess a charged residue in the transmembrane domain that could 
permit interaction with the DAP12 adapter molecule. The only 
previous description of NKG2H expression analyzed a TCRαβ+ 
CD8+ T cell clone and reported that NKG2H was an activating 
receptor able to trigger redirected lysis in a TCR-independent 
manner (18). However, further progress in understanding the 
biology and function of the orphan NKG2H receptor including 
signaling, molecular interactions, and ligand binding has been 
seriously hampered due to lack of monoclonal antibodies specific 
for this molecule.
We now show that NKG2H associates with both the DAP10 
and DAP12 signaling adapter molecules, suggesting that NKG2H 
will act as an activating receptor. Using a new commercially 
available monoclonal antibody (mAb) specific for NKG2H, we 
have carried out the first study of the phenotype and functional 
capacity of lymphocytes expressing the NKG2H receptor. These 
data show that the NKG2H receptor is expressed on low numbers 
of peripheral blood lymphocytes, but that activation of these 
NKG2H-expressing cells markedly reduces the activation and 
proliferation of other T cells in the culture. Although the mecha-
nism of action of this receptor is as yet unknown, we have also 
shown that this suppressive activity did not depend on the release 
of soluble factors or recognition of MHC class I molecules.
MaTerials anD MeThODs
Transfection of 293T cells with nKg2h 
constructs
A construct encoding full length NKG2H tagged with a c-myc 
epitope at the N-terminus was prepared by PCR using the 
oligonucleotides 5′-cgggatccgccaccatggcatcaatgcagaagctgatctca-
gaggaggacctgaataaacaaagaggaaccttctc-3′ and 5′-ttttccttttgcg-
gccgcttatgcaatcataatatcatttctg-3′ and cloned into the pHR-sin 
vector (19). Plasmids encoding CD94, FLAG-DAP12 (gifts of C. 
Chang), and DAP10-GFP have been described previously (20–
22). 293T  cells were transfected with the indicated plasmids 
using the JETPEI reagent according to the manufacturer’s 
recommendations.
reagents
The 9E10 mAb (ATCC CRL-1729), specific for the human c-myc 
gene product, was purified from hybridoma supernatant. FLAG-
tag and GFP-specific antibodies were purchased from Sigma-
Aldrich and Santa Cruz Biotechnology.
Conjugated antibodies for blood lymphocyte subpopula-
tions were from BioLegend and Beckman Coulter, as follows: 
CD3-FITC (Clone UCHT1); CD3-PacificBlue (Clone OKT3); 
CD4-APC (Clone OKT4); CD8-PeCy7 (Clone RPA-T8); 
CD45RA-ECD (Clone 2H4LDH11LDB9); CD45RO-FITC 
(Clone UCHL1); CD56-PE (Clone MEM-188); CD69-APC/Cy7 
(Clone FN50); CD56-PerCP/Cy5.5 (Clone N901). Monoclonal 
antibodies specific for NKG2H (Clone 633810), NKG2A (Clone 
131411), and NKG2C (Clone 134591) were purchased from 
R&D Systems (Abingdon, UK). To validate the specificity of 
the commercial NKG2H mAB, we stained the NKL cell line 
transfected, or not, with an NKG2H cDNA cloned in the into 
the lentiviral vector pHRSIN-C56W-UbEM (a gift of Prof Paul 
Lehner, Cambridge Institute for Medical Research, Cambridge) 
to simultaneously express NKG2H under the SFFV promoter and 
the GFP derivative protein, Emerald, under a ubiquitin promoter. 
Untransfected NKL cells stain positively for NKG2A, NKG2C, 
and NKG2D expression, but only bind the NKG2H mAb after 
lentiviral transduction with the NKG2H cDNA (Figure S1 in 
Supplementary Material).
Purified human anti-CD3 (ATCC, Clone CRL-8001) and anti-
CD28 (BD Biosciences, Clone CD28.2) antibodies were used in 
the immobilized stimulation assays. Secondary PE-conjugated 
anti-mouse Ig antibody was purchased from DakoCytomation. 
Blocking MHC class I-specific antibody (HP-1F7), a gift of Dr. 
Miguel López-Botet (UPF, Barcelona), has been described previ-
ously (23). Annexin-V-FITC and 7AAD were purchased from 
Beckman Coulter. The isotype controls used in the flow cytom-
etry and functional experiments were mouse MOPC-21 (IgG1, 
purchased from Sigma) and OX-68 (IgG2a, ECACC Hybridoma 
Collection: OX-68).
Western Blot and immunoprecipitation
Cells were lysed in 1% digitonin (in 0.12% Triton X-100, 150 mM 
NaCl, 20 mM Triethanolamine, pH 7.8, and 0.02% sodium azide). 
After centrifugation to remove insoluble material and preclearing, 
the indicated antibodies were added to the lysates to a final con-
centration of 5 µg/ml. After incubation on ice, the immune com-
plexes were recovered using Protein G sepharose and analyzed by 
SDS-PAGE and western blotting using specific antibodies.
Peripheral Blood Mononuclear cell 
(PBMc) culture
This study was carried out in accordance with the recommenda-
tions of the ethical committee of the CSIC, Madrid, with written 
informed consent from all subjects. All subjects gave written 
informed consent in accordance with the Declaration of Helsinki. 
The protocol was approved by the local ethical committee of the 
Regional Transfusion Centre, Madrid.
Peripheral blood mononuclear cells were isolated from anony-
mous healthy volunteers by Ficoll-Hypaque (GE Healthcare) 
FigUre 1 | NKG2H can associate with both the DAP12 and DAP10 
signaling adapter molecules. 293T cells were transfected with expression 
vector encoding N-terminally c-myc tagged NKG2H, wild-type CD94, and 
DAP12 (a) or DAP10 (B) as indicated and cell lysates were prepared. 
Samples were immunoprecipitated with either an isotype control or the 
c-myc-specific 9E10 mAb and then 20 µg of the whole cell lysates or the 
entire immunoprecipitates were analyzed by western blot using the indicated 
antibodies. The data are representative of three to five experiments.
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density gradient centrifugation. Purified PBMCs were cultured 
in RPMI supplemented with 10% human serum (HS) (Sigma 
Aldrich), 2 mM l-glutamine, 10 mM HEPES, 100 U/ml penicil-
lin, 100 U/ml streptomycin, and 50 µM β-mercaptoethanol and 
incubated in a humidified incubator at 37°C and 5% CO2.
Flow cytometry
For immunofluorescence staining of PBMCs, cells were washed 
with PBS containing 1% FBS, 0.5% BSA, and 0.05% sodium azide 
(PBA), pre-treated with 1% normal HS to block non-specific 
binding of mAbs to FcR. Subsequently, PBMC were stained with 
the unlabeled NKG2H-specific mAb, or IgG2a isotype control, 
and PE-labeled F(ab′)2 fragments of goat anti-mouse Ig (Dako). 
These samples were then blocked with 10% normal mouse serum 
before being stained with directly labeled mAbs specific for 
other markers (CD3, CD4, CD8, etc.). Samples were analyzed 
using Gallios (Beckman Coulter) or Cytomics FC500 (Beckman 
Coulter). Flow cytometry data were analyzed using either Kaluza 
v1.2 or FlowJo V9.6.2 software.
stimulation of PBMc Using immobilized 
antibody
To immobilize the antibodies used for stimulation, 24-well plates 
were coated with purified human anti-CD3, anti-CD3/CD28, or 
anti-CD3/NKG2H mAbs in PBS and incubated for 2–3 h at RT. 
The mAb concentration is specified in each experiment. Unbound 
mAb was removed by washing with PBS. 1.5–2.106 PBMCs per 
well were added to the mAb coated plates in RPMI containing 
10% HS and incubated for 48 or 72 h at 37°C and 5% CO2 in a 
humidified incubator. After this period of incubation, cells were 
collected and analyzed by flow cytometry.
Proliferation assay
Peripheral blood mononuclear cells were resuspended in RPMI 
and incubated for 5–7 min at 37°C in the incubator with the intra-
cellular fluorescent dye CFSE at a final concentration of 2.5 µM. 
After two washes, CFSE-labeled PBMCs were cultured in 24-well 
plates to which mAb had been pre-absorbed as described. Flow 
cytometry analyses of CFSE-labeled cells were performed on days 
2, 3, and 4 after stimulation.
cell Viability assay
Peripheral blood mononuclear cells stimulated using immobi-
lized antibodies were pre-stained, washed with PBS, and stained 
with Annexin-V FITC and 7AAD in annexin-binding buffer 
(Invitrogen) following the manufacturer’s instructions.
supernatant Transfer experiments
For supernatant transfer experiments, PBMCs from healthy 
donors were stimulated with the indicated immobilized antibod-
ies for 48 h, after that, the supernatant was collected and frozen 
at −20oC (“donor culture”). PBMCs from healthy donors were 
purified and stimulated on plates pre-coated with CD3-specific 
mAb (“recipient culture”). Stored supernatant from the “donor 
cultures” was diluted 1:2 or 1:5 in complete RPMI medium supple-
mented with 10% HS and added to the corresponding “recipient 
culture.” PBMCs stimulated with immobilized anti-CD3 antibody 
in complete RPMI supplemented with 10% HS were used as a 
control. After 48 h, the percentage of CD69-expressing cells was 
determined by flow cytometry.
resUlTs
nKg2h can Pair with both the DaP10 and 
DaP12 signaling adapter Molecules
The high degree of sequence similarity between NKG2C, NKG2E, 
and NKG2H (Figure S2 in Supplementary Material) led to the 
prediction that NKG2H would associate with the adapter mol-
ecule DAP12 to form an activating immunoreceptor complex 
(18). To investigate this possibility, we transfected 293T cells with 
a c-myc tagged NKG2H construct in the presence and absence 
of CD94 and FLAG-tagged DAP12. Western blot analysis of 
anti-myc immunoprecipitates of transfected cells, lysed in 1% 
digitonin buffer, confirmed that NKG2H associates with DAP12 
and showed that this did not depend on CD94 (Figure  1A). 
Surprisingly, NKG2H was also observed to associate with the 
DAP10 adapter molecule (Figure  1B). These data strongly 
suggested that NKG2H was likely to be an activating receptor; 
therefore, the next set of experiments addressed the issues of 
which immune cells expressed this receptor and what were the 
functional consequences of receptor ligation.
nKg2h is Mainly expressed by 
subpopulations of T cells in healthy Donors
Flow cytometry analysis of freshly isolated PBMCs from a panel of 
healthy individuals was used to characterize the cell populations 
FigUre 2 | Expression of NKG2H in peripheral blood mononuclear cells 
(PBMCs) from healthy donors. PBMCs isolated from healthy individuals were 
analyzed by flow cytometry. (a) Gating strategy. NK cells were defined by 
gating the CD3−CD56+ cells within the lymphocyte region, defined by forward 
and side scatter parameters. CD56high and CD56dim NK subsets were 
analyzed separately. For T cells, CD8+ and CD4+ T cells were analyzed within 
the CD3+CD56− region. CD3+CD56+ double positive effector lymphocytes 
were also gated as CD3+CD56+CD8+ and CD3+CD56+CD4+. The percentage 
of NKG2H-positive cells was analyzed within each region. (B) The percentage 
of NKG2H+ cells in the different lymphocyte populations was determined in 
PBMCs from five different healthy individuals. Data show the mean and SD of 
independent experiments after subtraction of isotype control values. (c) The 
percentage of NKG2H+ cells expressing CD45RA, CD45RO, or both 
CD45RA and RO in different populations of T cells was determined in PBMCs 
from five different healthy individuals. Data show the mean and SD of 
independent experiments.
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expressing NKG2H at the cell surface. A five-color staining 
strategy, using a combination of anti-CD3, CD4, CD8, CD56, and 
anti-NKG2H mAbs was used to analyze NKG2H expression on 
the different PBMC subsets defined by these surface markers. The 
gating strategy for these analyses is shown in Figure 2A.
Despite some variation between blood donors, NKG2H was 
consistently found expressed on the surface of low numbers of 
PBMCs (Figure 2B). Little or no NKG2H receptor was expressed 
by freshly isolated NK cells, either the CD56dim or CD56bright subsets. 
However, both CD3+CD56+ and CD3+CD56− T cells expressed 
NKG2H, particularly CD8+CD56+T cells. It is interesting to note 
that NKG2H was first identified and cloned from a human CD8+ 
T  cell clone (18). These data were confirmed in independent 
experiments using polyclonal sera obtained by immunization 
of mice with a GST-fusion protein expressing 33 C-terminal 
amino acids of NKG2H (Figure S3 in Supplementary Material). 
As expected, preincubation of the NKG2H-specific mAb with 
peptide antigen markedly reduced the staining observed (Figure 
S4 in Supplementary Material).
Expression of CD45RA and CD45RO splice isoforms is often 
used to analyze the differentiation state of T  cells, CD45RA 
denoting naïve/effector T cells and CD45RO denoting memory 
T cells (24). Analysis of CD45RA and RO expression by NKG2H+ 
cell subsets revealed that, although the CD45RO antigen was 
present on some NKG2H+ T cells, the vast majority of these cells 
expressed the CD45RA marker (Figure  2C). Consistent with 
published data (25), NK cells, whether NKG2H+ or not, expressed 
the CD45RA isoform almost exclusively (not shown).
activation of nKg2h expressing cells 
Markedly reduces the activation of Other 
T cells in the culture
The association of NKG2H with the signaling adapter molecules 
DAP12 and DAP10 suggests that NKG2H will likely be an activat-
ing receptor. This idea is consistent with previous observations 
that engagement of NKG2H could trigger both early activation 
events such as Ca2+ mobilization, and late effector functions 
such as induction of TCR-independent cytolytic activity and 
IFN-γ production in a T cell clone maintained in IL-2 (18). To 
establish the functional consequences of ligation of the NKG2H 
receptor on freshly isolated resting T cells, PBMCs were exposed 
to a suboptimal dosage of immobilized anti-CD3 antibody in 
combination with anti-NKG2H antibody for 48 h. As controls, 
PBMCs were incubated either with immobilized anti-CD3 anti-
body alone or a combination of anti-CD3 with an isotype control 
IgG2a antibody. Strikingly, simple inspection by light microscopy 
revealed that those cell cultures stimulated with the combination 
of CD3 and NKG2H-specific mAbs appeared far less activated 
than the control cells after 48 h of stimulation (Figure 3A), and 
these differences were much more pronounced after 72  h (not 
shown). Flow cytometry analysis confirmed that only a small 
proportion of T  cells in these cultures expressed NKG2H at 
the cell surface (Figure  3B); nevertheless, consistent with the 
observations made by light microscopy, there was a significant 
decrease of the percentage of CD69-expressing cells in cultures 
stimulated with anti-CD3/NKG2H antibodies compared to 
cultures stimulated only with anti-CD3 (Figure 3C). In control 
experiments, co-incubation of the anti-CD3 mAb with other 
mAbs, including the NKG2H-specific mAb had no significant 
effect on the amount of anti-CD3 mAb immobilized (Figure S5 
in Supplementary Material).
FigUre 3 | Lymphocyte activation is reduced after cross-linking peripheral blood mononuclear cells (PBMCs) with antibodies directed against CD3 and NKG2H.  
(a) Microscope images of PBMCs from three representative healthy donors incubated in plates pre-coated with anti-CD3 (1 µg/ml), anti-CD3/IgG2a control, or 
anti-CD3/NKG2H (1/10 µg/ml) antibodies for 48 h. No coating (PBS) was used as a negative control. (B) NKG2H expression on T cells in the cultures under different 
stimulation conditions. (c) Quantitative analysis of the percentage of activated cells (expressing CD69) after anti-CD3/IgG2a control or anti-CD3/NKG2H stimulation. 
Mean data of five independent experiments are represented; *p < 0.05; **p < 0.01.
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Since only a small proportion of PBMCs express NKG2H at 
the cell surface, these results suggest that activation of NKG2H-
expressing T cells might negatively regulate the activation and/or 
proliferation of other T cells in the culture.
activation of nKg2h expressing cells 
Markedly reduces the Proliferation of 
Other cells in the culture
To elucidate whether the decrease of CD69 expression on T cells, 
after NKG2H stimulation, was accompanied by growth changes 
in the PBMC culture, T  cell proliferation was also analyzed. 
CFSE-labeled PBMCs were exposed to immobilized anti-CD3/
NKG2H or control anti-CD3 antibodies and cell proliferation 
was evaluated on days 2, 3, and 4 of the culture. As shown in 
Figures 4A,B, the proliferation of T cells in cultures stimulated 
with mAbs to CD3 and NKG2H was significantly reduced 
compared to control cells. Thus, co-cross-linking of TCR/CD3 
and NKG2H on the small fraction of T cells expressing the latter 
receptor, significantly inhibited the activation and proliferation of 
the majority of T cells in the culture.
ligation of nKg2h, but not nKg2a or 
nKg2c, impairs PBMc activation
Both, the inhibitory CD94/NKG2A and activating CD94/NKG2C 
receptors have been described to be expressed and functional in 
αβ and γδ CD8+ T cells (13, 15, 26). Accordingly, to test whether 
FigUre 4 | NKG2H stimulation reduces proliferation of lymphocytes in the cell culture. (a) Representative flow cytometry histograms of CFSE-labeled peripheral 
blood mononuclear cells (PBMCs) stimulated with anti-CD3 (1 µg/ml) or anti-CD3 and NKG2H (1/10 µg/ml, respectively) antibodies for 2, 3, or 4 days. Leukocytes 
were gated on forward and side scatter, and the plots show CD3 staining vs. CFSE fluorescence. (B) Representation of the proliferation index. Mean data and SDs 
of several independent experiments with six different donors are represented; *p < 0.05; **p < 0.01, ***p < 0.001. M0: no mitosis, M1–M5: number of mitotic 
divisions.
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the observed reduction in T  cell activation after anti-CD3/
NKG2H cross-linking was a specific feature of NKG2H receptor 
signaling or could also be produced after stimulation by other 
NKG2 family members, the previous experiments were replicated 
using PBMCs cultured in plates where combinations of anti-CD3/
NKG2C and anti-CD3/NKG2A antibodies had been immobi-
lized. As previously, simultaneous exposure to anti-CD3 and anti-
NKG2H antibody significantly decreased the percentage of T cells 
expressing the activation marker CD69. In contrast, treatment 
with anti-CD3/NKG2C or anti-CD3/NKG2A had no significant 
effect on T cell activation compared to PBMCs stimulated only 
with anti-CD3 (Figure 5). Altogether, these observations support 
that stimulation through NKG2H, but not NKG2A or NKG2C, 
specifically leads to reduced T cell activation in the culture. These 
experiments also argue against the idea that the reduced CD3-
induced activation seen after co-ligation with NKG2H is due to a 
reduction in the efficiency of immobilization of anti-CD3 mAb in 
the presence of a 10-fold excess of another mAb.
activation of nKg2h+, but not nKg2a+ or 
nKg2c+, cells is associated with the 
induction of cell Death in the culture
The previous observations raised the question as to how activa-
tion of the 0.5–1% of T cells expressing NKG2H could modulate 
the activation of the remaining lymphocytes that had no appreci-
able expression of NKG2H. One possible solution to this conun-
drum was that activation of the minority NKG2H-expressing 
FigUre 6 | NKG2H stimulation results in decreased cell survival. Purified 
peripheral blood mononuclear cells (PBMCs) were activated on plates coated 
with anti-CD3 (1 µg/ml) or anti-CD3/NKG2H (1/10 µg/ml) antibodies for 48 h. 
In parallel, stimulation of PBMCs using immobilized anti-CD3 (1 µg/ml), and 
the combination of anti-CD3/NKG2A and anti-CD3/NKG2C antibodies 
(1/10 µg/ml) was also carried out (data not shown). Cell survival was analyzed 
by Annexin V/7AAD staining. (a) Representative flow cytometry dot plots  
(B) Changes in the percentages of cells positive for Annexin V and 7AAD 
were calculated. Mean data and SDs of six experiments with different healthy 
donors are represented; *p < 0.05.
FigUre 5 | NKG2H, but not NKG2A or NKG2C cross-linking leads to 
decreased lymphocyte activation. 24-well plates were coated with anti-CD3 
(1 µg/ml), anti-CD3/NKG2A (1/10 µg/ml), anti-CD3/NKG2C (1/10 µg/ml), or 
anti-CD3/NKG2H (1/10 µg/ml) antibodies. Purified peripheral blood 
mononuclear cells (PBMCs) from healthy donors were isolated and cultured 
in antibody-coated plates for 48 h. After this time, the cells were collected, 
stained with anti-CD69 antibody and analyzed by flow cytometry. Analyses 
are gated on leukocytes (based on forward and side scatter). Representative 
data of three experiments from two different donors are shown; **p < 0.01.
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population could result in the induction of death of other T cells 
in culture. To explore whether the reduced proliferation of 
PBMCs after cross-linking by anti-CD3/NKG2H antibody could 
be due to reduced cell survival, purified PBMCs were stimulated 
with immobilized anti-CD3 or anti-CD3/NKG2H antibodies 
for 48  h and cell survival was measured by Annexin V/7AAD 
staining (Figure 6A). Remarkably, a significant increase of cell 
death was observed when activation of PBMCs was carried out 
in the presence of anti-NKG2H mAb (Figure 6B). By contrast, no 
significant changes in Annexin V/7AAD staining were observed 
in PBMCs treated with anti-CD3/NKG2A or anti-CD3/NKG2C 
antibodies (data not shown). These data clearly show that co-
stimulation with anti-NKG2H leads to lower levels of survival 
than control stimulations with anti-CD3 mAb alone.
cell–cell interactions, but not soluble 
Factors or Mhc class i are necessary for 
nKg2h action
The data outlined so far indicate that cultures stimulated with 
anti-NKG2H antibody showed reduced activation, a decreased 
proliferative response, and an increased level of cell death. These 
multiple cellular functions could depend either on soluble factors 
or they could require direct cell contact.
To investigate the potential role of soluble factors released 
into the media after anti-NKG2H stimulation of PBMCs, cell-
free supernatants collected from cultures after stimulation with 
either anti-CD3 or anti-CD3/NKG2H antibodies, were added at a 
range of different dilutions to a new set of cell cultures stimulated 
with anti-CD3 mAb alone. No differences in the induction of the 
activation marker CD69 were observed in any of the conditions 
used (Figure 7A), strongly suggesting that the release of soluble 
factors was not required for the NKG2H-dependent reduction 
in cell activation and so, by elimination, cell–cell interactions are 
probably necessary for NKG2H to elicit the cellular effects shown 
previously.
Blockade of MHC class I molecules, using the mAb HP-1F7, 
which detects all classical HLA class Ia, as well as non-classical 
class Ib molecules including HLA-E (23, 27), did not revert the 
reduced activation of cells cultured with NKG2H-specific anti-
body (Figure 7B). These data suggest that MHC class I molecules 
are not involved in the mechanism of action of NKG2H, consist-
ent with previous data showing that cell surface HLA-E did not 
trigger cytotoxicity by the K14B06 NKG2H+ T cell clone (18).
DiscUssiOn
The NKG2H receptor, a splice variant of NKG2E, was first 
described as a new member of NKG2 family by Bellon et al. in 
FigUre 7 | NKG2H suppression of lymphocyte activation is not mediated by 
a soluble factor and is not blocked by antibodies to MHC class I. (a) 
Supernatants from a culture of peripheral blood mononuclear cells (PBMCs) 
grown on antibody-coated plates were collected and used at 1:2 and 1:5 
dilutions, as indicated, to stimulate a second culture of PBMCs. Cell culture 
media or the indicated antibodies were used as controls. After 48 h of 
incubation with the indicated supernatant, cells were harvested, stained for 
CD69 as a surface activation marker and analyzed by flow cytometry. 
Leukocytes were gated on forward and side scatter and stained for CD3 and 
CD69. Mean data and SDs of three experiments with different donors are 
represented. SN—supernatant collected from cells stimulated with the 
indicated antibody. (B) Freshly purified PBMCs were cultured on plates 
coated with anti-CD3 (1 µg/ml), anti-CD3/IgG2a control, or anti-CD3/NKG2H 
(1/10 µg/ml) antibodies for 48 h in the presence or absence of purified MHC 
class I-specific mAb (clone HP-1F7 at 10 µg/ml). The means and SDs of four 
experiments with different donors are represented; **p < 0.01.
8
Dukovska et al. NKG2H Negatively Regulates Lymphocyte Activation
Frontiers in Immunology | www.frontiersin.org March 2018 | Volume 9 | Article 390
1999. However, to our knowledge, no follow-up studies have been 
published, and presumably it is the lack of specific mAb reagents 
that has blocked progress in understanding the immunological 
function of this receptor. The NKG2 family encodes both activat-
ing and inhibitory receptors and this function correlates with the 
presence or absence of ITIM elements in the cytoplasmic tail and 
the presence or absence of a charged, basic residue in the TM 
domain that mediates association with ITAM-containing signal-
ing adapter molecules like DAP12. NKG2H is highly homolo-
gous, in the cytoplasmic and TM regions, to the NKG2C receptor 
that associates with DAP12 therefore it was not surprising that 
DAP12 co-immunoprecipitated with NKG2H. The observation 
that NKG2H was also able to complex with DAP10 was however, 
unexpected. Human NKG2D associates with DAP10 and splice 
variants of murine NKG2D are able to associate with both DAP10 
and DAP12 (28, 29). Experiments with chimeric NKG2D recep-
tors and DAP10 and DAP12 signaling adapters have shown that 
the principal determinant(s) controlling the specificity of adapter 
association lie in the TM domain (30, 31), but the molecular details 
controlling receptor–adapter pairing are not known. Inspection 
of sequence alignments of NKG2H with other members of the 
NKG2 family has not provided any insights into the promiscuous 
assembly of NKG2H with both the DAP10 and DAP12 signaling 
adaptor molecules; thus, further studies will be required to dissect 
the biochemical basis of this phenomenon.
The availability of a new anti-human NKG2H-specific mAb 
allowed us to both define the lymphocyte populations that express 
NKG2H receptor and study the functional consequences of 
receptor cross-linking. The NKG2H antibody was raised against 
a specific NKG2H peptide sequence and was shown to specifically 
stain NKL cells transduced to express NKG2H.
NKG2H was expressed at low levels on the surface of a small 
fraction of lymphocytes derived from healthy donors. Although 
some expression of NKG2H was detected on NK  cells, this 
molecule was preferentially present on T cells and, in particular, 
CD8+CD56+ T cells. These lymphocytes expressing the NKG2H 
receptor, were more likely to express CD45RA+ than CD45RO+; 
however, there was also a significant population of CD45RA/
CD45RO double expressing NKG2H+CD56+ T  cells. CD56+ 
T cells have been reported to express higher levels of NK mark-
ers, but not to lyse standard NK-susceptible targets and actually 
exhibit a relatively quiescent transcriptional profile (32). Thus, 
overall, our data indicate that NKG2H in healthy individuals 
is expressed preferentially on naïve/effector cells rather than 
memory T  cells. Previous observations indicate that CD94/
NKG2A can be found expressed by both effector and memory 
T  cells, whereas CD94/NKG2C is mainly expressed by highly 
differentiated CD8+ effector T cells (33).
Although NKG2H associates with DAP12 and thus would 
be expected to act as an activating or co-stimulating receptor, 
antibody ligation of NKG2H in the presence of suboptimal doses 
of stimulatory anti-CD3 antibody actually resulted in a profound 
inhibitory effect on T cell activation in these cultures. By contrast, 
stimulation of lymphocytes from healthy donors, with either 
anti-CD3/NKG2A or anti-CD3/NKG2C antibody mixtures had 
minimal effects on T cell activation in these cultures, indicating 
that the observed inhibitory effect was specific for NKG2H recep-
tor signaling. These data, together with the flow cytometry details 
of preferential expression of the NKG2H receptor on a subset 
of CD3+CD8+CD56+ cells, implies that the T cells activated by 
NKG2H receptor signaling may negatively regulate the responses 
of other T cells. In this context, it is tempting to speculate that 
the CD3+CD56+CD8+CD45RA+NKG2H+ T cells could be related 
to a recently identified population of cytolytic CD3+CD8+CD5
6+CD161− regulatory T  cells (CD8+ Treg) present in human 
peripheral blood where the large majority of these cells express 
the CD45RA marker (34). Further studies are needed to deter-
mine how NKG2H-expressing T  cells are related to this CD8+ 
Treg subset, which selectively regulates activated CD4+ T cells, 
and the possible implication of the NKG2H expression on these 
cells, but these experiments will depend on being able to purify 
and grow NKG2H+ T cells in vitro for detailed characterization 
including how the level of receptor cross-linking is related to 
positive or negative signaling and the downstream signaling 
events that occur after NKG2H stimulation.
Experiments using culture supernatants collected after 
anti-CD3/NKG2H stimulation of PBMCs revealed that the 
suppressive activity could not be accounted by secretion of 
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soluble factor(s) from NKG2H-stimulated cells. A requirement 
for cell contact for NKG2H to mediate inhibition suggests that 
these cells act directly on other T cells to prevent activation and 
interestingly, co-ligation of CD3 and NKG2H was associated 
with the induction of significant levels of T cell death in these 
cultures. The simplest interpretation of these data is that the 
subsets of T cells that express NKG2H negatively affect T cell 
activation by the induction of apoptosis in bystander respond-
ing T cells.
It is still not clear whether this effect is mediated by upregu-
lation of NKG2H expression after TCR-stimulated activation 
followed by NKG2H ligation and cell intrinsic inhibition or 
whether the lymphocytes that express NKG2H prior to stimula-
tion become able to inhibit the activation of other T cells in trans. 
Either scenario would explain the failure of multiple attempts 
to expand populations of purified NKG2H+ T cells in vitro in 
the presence of exogenous IL-2 or combinations of IL-2 and 
the mitogen PHA (data not shown). Alternatively, it cannot 
be excluded that the proliferative capacity of NKG2H+ T cells 
is limited and/or that specific co-stimuli and/or cytokines are 
necessary to enable these cells to divide. Such regulation has not 
been observed for other activating NKR such NKG2C (15, 26), 
but it would be reminiscent of some features of the CTLA-4/B7 
regulatory loop (35).
In this context, it is worth noting that, although DAP12 is 
generally thought of as an ITAM-containing adapter molecule 
for activating receptors, its function is more complex (36, 37). 
DAP12 associated receptors can downregulate TLR-dependent 
responses in macrophages as well as CD16-dependent responses 
in NK  cells (38, 39). Similarly, DAP12 down-modulates the 
cytokine production by plasmacytoid dendritic cell in vivo dur-
ing murine cytomegalovirus infection (40) and DAP12-deficient 
B cells are hyper-responsive after stimulation with anti-IgM or 
CpG, suggesting that DAP12-coupled receptors negatively regu-
late B cell-mediated adaptive immune responses (41).
It is worth noting that our observation that NKG2H 
stimulation triggers inhibition of responses differs from the 
initial report where aggregation of the putative CD94/NKG2H 
heterodimer expressed on a T cell clone triggered cytotoxicity 
and IFN-γ production in a TCR-independent manner (18). 
This discrepancy might simply reflect that in those experiments 
receptor cross-linking was done using a CD94-specific mAb 
and the presence of an activating NKG2C molecule on the clone 
was never excluded, whereas in our experiments NKG2H was 
stimulated by a mAb specific for this receptor. It is also pos-
sible that adaptations in the T cell clone during the long-term 
in vitro culture necessary for its derivation may have selected for 
a T cell whose responsiveness may not be representative of the 
full spectrum of responses of freshly isolated peripheral blood 
T cells in short-term culture.
No ligands for NKG2H have been identified so far. RMA-S 
cells transfected with HLA-E and cultured in the presence of 
peptides that stabilize HLA-E on the surface were not recog-
nized by the T cell clone expressing NKG2H (18). Similarly, in 
our experiments, addition of an anti-HLA class I mAb (HP-
1F7), which detects all classical and non-classical HLA class 
I molecules including HLA-E (23, 27), failed to completely 
recover the activation of the PBMCs in the cultures stimulated 
with anti-CD3/NKG2H antibodies. Finally, although it was sug-
gested that the splice variant NKG2H, might behave similarly 
to NKG2E and probably bind to HLA-E with similar affinity 
(16); so far, there are no data that demonstrate an interaction 
between HLA-E and NKG2H. In aggregate therefore, the avail-
able data suggest that it is possible that NKG2H recognizes and 
binds molecules that are not related, at least to conventional 
HLA-E-leader peptide loaded complexes. However, our 
attempts to produce soluble NKG2H molecules, which would 
greatly facilitate the search for possible ligands for this receptor, 
have been unsuccessful. Similar difficulties in expression and 
refolding have also been reported for the ectodomain of NKG2E 
molecule (16).
In summary, here we have described for the first time the 
population of cells that express the NKG2H receptor, mainly 
CD3+ T cells, and the effects inserted on lymphocyte function 
following NKG2H receptor ligation. Although the exact role 
of NKG2H receptor in T  cell activation control remains to be 
confirmed, the present study suggests that T cells expressing this 
receptor may act in a negative regulatory circuit to modulate 
T cell activation.
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